miragen therapeut clinic stage biopharmaceut compani
develop microrna-bas therapi diseas high unmet medic need lead-
candid cobomarsen initi develop treatment mycosi
fungoid mf common form cutan cell lymphoma ctcl initi
phase data drug show treatment well toler encourag sign
clinic activ kol consult emphas need safe durabl treatment
patient mf highlight need improv treatment option miragen plan
report updat on-going phase studi american societi hematolog
annual meet decemb repres miragen next major catalyst
point discuss
miragen develop cobomarsen way treat select hematolog
malign overexpress cobomarsen chemic modifi anti-
mir oligonucleotid bind seed sequenc matur oncomir
overexpress variou hematolog malign includ mycosi fungoid
mf form cutan cell lymphoma ctcl result augment effector
kinas signal cell prolifer increas cell surviv phase data basket
studi evalu safeti toler cobomarsen patient mf chronic
lymphocyt leukemia cll diffus larg cell lymphoma dlbcl adult cell
leukemia/lymphoma atll shown therapi well toler sign
clinic activ patient mf therebi provid mechanist proof-of-concept
note given initi data may potenti cobomarsen
hematolog malign atll fatal diseas caus human cell leukemia
viru type miragen recent show encourag data atll patient
knowledg cobomarsen advanc mirna-bas therapi address
oncolog indic field rnai therapeut recent experienc resurg
alnylam onpattro patisiran approv polyneuropathi
hereditari amyloidosi approv cap decad failur rnai therapeut
space mostli relat issu immunogen deliveri miragen believ
work mani problem plagu mirna therapeut compani
past well posit advanc clinic candid
interim phase data cobomarsen
initi phase ii trial ctcl
expect releas phase ii data remlarsen cutan fibrosi
expect result phase ii ctcl trial
year left
short interest float
analyst certif disclosur pleas see page
kol highlight need long-last toler therapi mf earli phase data cobomarsen
encourag accord kol consult need safe durabl treatment patient
mf kol highlight manag later stage mf stage iv prevent stage ib diseas
progress stage iib beyond press unmet need indic roughli
patient earli stage diseas stage ib/iib progress receiv avail treatment exampl respons
rate histon deacetylas inhibitor hdaci approv system treatment option mf patient vari
respons often short-liv last month
term safeti toler kol spoke emphas sever side effect concern associ
current treatment option view limit use chief among metabol relat
retinoid myalgia fatigu often experienc patient receiv interferon alpha gastro-intestin issu
neutropenia fatigu link histon deacetylas inhibitor hdaci treatment point mf
chronic diseas patient often want remind live malign consequ
kol highlight need therapi durabl safe access consult encourag
data present thu far cobomarsen mswat mswat iv cohort
believ drug activ eager see data regard efficaci durabl
said miragen slate present data mf patient on-going phase studi year american
societi hematolog annual meet decemb
undepreci market treatment target stage ib-iii mf mf common form ctcl
affect person us eu roughli patient stage ib mf
progress patient popul miragen seek target cobomarsen stage ib-iii base analys
estim mf patient elig cobomarsen treatment us eu note
mechanist rational cobomarsen hematolog malign includ dlbcl cll atll
repres addit market vari level unmet need
replac offer attract opportun fibrosis-rel patholog miragen develop
remlarsen replac therapi patholog fibrosi phase studi evalu drug
healthi volunt show safe well-toler recent compani report posit preclin
data remlarsen murin model ocular fibrosi miragen current sponsor phase ii remlarsen
patient histori keloid updat expect view fibrot indic appeal space
remlarsen given mechanist rational replac fibrosi sizabl market potenti
partner larg pharma player
third quarter result septemb miragen cash cash equival short-
term invest million use oper activ six month end septemb
research develop expens third quarter compar
period compani announc increas research develop expens due
prepar phase ii solar studi slate initi gener administr
expens second quarter compar third quarter compani report
net loss per share third quarter compar net loss per share
third quarter
tabl content
overexpress variou hematolog malign link poor clinic outcom
bind regul cancer
preclin develop cobomarsen
cobomarsen addict lymphoma
mycosi fungoid mf common cutan t-cell lymphoma ctcl
addit indic expans potenti cobomarsen
market cobomarsen
cobomarsen shown sign clinic activ mf
basket phase trial cobomarsen mf ctcl atll dlbcl
solar phase ii clinic trial mycosi fungoid
cobomarsen competit landscap need therapi toler long-last ctcl
remlarsen gener mimic microrna treat fibrot indic
remlarsen ocular fibrosi
mirna therapeut develop miragen
inhibitor promot angiogenesi
inhibitor treat neurodegener
risk invest
clinic stage biopharma compani develop micro-rna mirna target therapi
diseas high unmet medic need compani leverag mirna platform regul gene express
use distinct mechan first employ anti-mir way bind inhibit mirna therebi increas
express protein interest second modal mirna mimet design reduc protein express
miragen employ clinic develop plan aim acceler timelin reduc develop risk
strategi revolv around demonstr mechanist proof concept rare genet defin diseas
seek approv within registr phase ii/iii framework lead candid cobomarsen anti-mir direct
oncomir upregul sever hematolog malign includ mycosi
fungoid mf form cutan cell lymphoma ctcl adult cell lymphoma/leukemia atll among
other cobomarsen demonstr favor safeti profil encourag sign clinic activ phase
basket studi miragen plan initi phase ii solar studi evalu cobomarsen patient mf
compani also develop replac therapi
treatment fibrot diseas recent phase studi healthi volunt establish safeti toler
remlarsen on-going phase ii studi patient histori keloid set readout data final
miragen partner servier privat evalu anti-mir separ studi
treatment ischemia data studi expect february/march compani development
pipelin shown figur
sinc discoveri non-cod rna field rnai therapeut attract increas interest target
drug discoveri develop main approach begun show therapeut potenti differ
diseas includ cancer infect small interf rna sirna microrna mirna
compar convent small molecul offer advantag abl act non-drugg target
allow develop broad product pipelin design address virtual gene
mirna biogenesi function mirna biogenesi begin transcript typic mirna gene
rna polymeras ii nucleu yield primari mirna primari mirna contain secondari hairpin
structur compos approxim nucleotid recogn nuclear
drosha rnaseiii activ liber hairpin yield pre-mirna duplex structur interspers
mismatch pre-mirna subsequ transport cytoplasm exportin undergo
process rnaseiii dicer gener matur mirna fulli process matur mirna duplex
nucleotid overhang phosphat end mirna biogenesi depict
matur mirna exert regulatori function first associ rna-induc silenc complex risc
form new complex known mirisc guid strand mirna usual strand less
stabli base-pair end upon incorpor guid strand mirisc mirna duplex unwound
current issu rnai therapeut deliveri develop journal control releas pp
et al microrna therapeut cancer emerg concept ebiomedicin pp
passeng strand discard mirna go bind mrna untransl region utr
partial complementar util seed sequenc compos first nucleotid locat
mirna basi partial complementar one mirna bind regul multipl target mrna
make attract therapeut modal heterogen diseas like cancer silenc mrna target occur
translat repress degrad deadenyl degrad decap exonucleas action
mirna therapeut approach half mirna gene locat cancer-associ genom
region result distinct subset solid tumor hematolog malign associ uniqu
mirna signatur make mirna potenti valuabl biomark therapeut subset mirna
known oncomir act oncogen tumor suppressor therapeut approach develop
leverag role mirna oncogenesi shown figur
oncogen mirna directli promot tumor growth persist target mrna encod tumor
suppressor protein member famili known oncogen mirna
mirna gener highli overexpress variou solid tumor hematolog malign one approach
combat overexpress use mirna inhibit therapi aim restor normal level mirna
express chemic modifi anti-mir oligonucleotid use bind matur mirna seed sequenc
prevent downstream target mrna bind repress challeng face optim
anti-mir oligonucleotid includ increas bind affin improv nucleas resist effici vivo deliveri
altern mutat result silenc loss function tumor-suppressor mirna also initi
contribut malign transform exampl famili shown target
multipl oncogen compon cell prolifer apoptosi reduc express either
mirna associ lung liver breast colon carcinoma develop chemically-modifi
synthet mirna memet may viabl option substitut deplet mirna order counteract
downregul anti-tumor activ numer studi valid mirna replac vitro
vivo model restor benefici mirna normal function level note liposom polymer-
base system result limit cellular uptak past although miragen believ optim
pipelin clinic candid bypass shortcom demonstr deliveri product
candid human
microrna therapi cancer molecular
overexpress variou hematolog malign link poor
microrna regul variou aspect cellular physiolog includ prolifer differenti cell death
normal condit play role hematopoiesi inflamm immun regul
hematopoiet cell differenti inflammatori respons well cell respons cell receptor
bcr tcr activ given role process surpris deregul associ
sever cell malign context cancer act oncomir transcrib
noncod rna b-cell integr cluster bic locu describ earlier oncomir mirna
implic tumorigenesi cancer transcript cellular consequ oncogen activ
depict figur includ augment effector kinas signal cell prolifer increas
overexpress mous lymphoid tissu result dissemin lymphoma resolv mir-
data suggest context lymphoma malign cell depend
express maintain cancer state therebi highlight potenti role therapeut agent design
regul activ
due et al biomark b-cell malign biom
babar et al nanoparticle-bas therapi vivo mous model
costinean et al pre-b cell prolifer lymphoblast leukemia high-grad lymphoma
figur transcript cellular consequ oncogen activ
evid overexpress associ aggress diseas patient certain
hematolog malign includ chronic lymphocyt leukemia cll diffus larg cell lymphoma
relat adult t-cell leukemia/lymphoma atll acut myeloid leukemia aml cutan cell
lymphoma studi evalu outcom adult cytogenet normal cn aml found
strong associ express level shorter disease-fre surviv overal surviv
os shown figur higher level express also associ lower odd achiev
cui et al influenc b-cell receptor signal associ aggress diseas chronic
eldin et al express signatur associ respons treatment within
differ subtyp b-cell malign biol aligarh
mole nicot emerg role mirna infect atll pathogenesi viru
ralfkiaer et al diagnost microrna profil cutan t-cell lymphoma ctcl blood
marcucci et al clinic role microrna cytogenet normal acut myeloid leukemia upregul
figur outcom cn-aml patient high express
cll patient high express associ significantli lower progress free surviv
mo ci vs mo ci trend toward shorter os mo ci
vs mo ci compar patient low given oncogen function mir-
hold potenti therapeut target inde preclin studi use chemic genet approach
modul function result decreas tumor growth vivo miragen current develop cobomarsen
anti-mir treatment nhl includ ctcl dlcbl atll therapi evalu
phase i/ii studi includ patient mycosi fungoid subset ctcl
bind regul cancer cobomarsen fall categori mirna inhibit therapi exert
clinic effect suppress short mixmer compos lock
nucleic acid lna dna residu interspers throughout molecul continu dna
residu short oligonucleotid also contain phosphorothio modif facil cellular uptak
promot nucleas resist system administr cobomarsen achiev broad tissu distribut favor
malign b-cell cell preferenti uptak oligonucleotid rel normal cellular uptak
occur via receptor-lik mediat endocytosi fluid-phas endocytosi depend concentr
cobomarsen make way cell incorpor complex bind process form
cobomarsen essenti act spong de-repress inhibitori activ therebi
rebalanc express target gene regul name involv myeloid expans differenti
inflamm
safeti profil cobomarsen demonstr favor safeti toler profil date phase studi
cobomarsen assess intraven subcutan intra-tumor deliveri method mf patient show
seriou advers event attribut treatment dose limit toxic note grade tumor flare
guinn et al express associ chemoimmunotherapi outcom modul bruton
tyrosin kinas inhibit ibrutinib leukemia jan
 et al olignucleotid uptak human hematopoiet cell increas leukemia relat cellular
seen one patient relat mg iv bolu inject drug grade worsen pruriti possibl tumor
flare occur twice one patient mg subcutan mg iv infus dose common
treatment-rel grade advers event neutropenia pruriti decreas lymphocyt count
common treatment relat advers event includ fatigu headach inject site pain
acut inflammatori toxic signific abnorm liver kidney detect
address two key safeti concern associ previou mirna therapeut
preclin develop cobomarsen order establish optim inhibitor panel
synthet oligonucleotid complimentari base-pair analyz measur magnitud
de-repress four direct downstream target picalm inppsd chang express
target gene increas dose cobomarsen escal statist signific differ
mol/l ctcl cell line high express addit extent target de-repress
ctcl cell line demonstr equival cobomarsen deliv facilit transfect
passiv deliveri establish lead candid studi
mf ctcl cell line cobomarsen demonstr phenotyp effect decreas cellular
prolifer figur increas apoptosi figur measur caspas activ comparison
bexaroten approv retinoid therapi ctcl us europ compar level cellular
prolifer cobomarsen littl effect
figur phenotyp effect cobomarsen overexpress cell line
seto beatti lynch hermreck tetzlaff duvic jackson cobomarsen
oligonucleotid inhibitor co-ordin regul multipl surviv pathway reduc cellular prolifer
surviv cutan t-cell lymphoma british journal haematolog
transcriptom analysi mf ctcl cell line direct downstream target
cobomarsen identifi primarili associ jak/stat mapk surviv signal
pathway cobomarsen demonstr simultan inhibit pathway stimul human
cell mf cell line measur reduc phosphoryl downstream protein similar observ
level compar pathway respect kinas inhibitor
effect cobomarsen compel cell line studi certain gene shown regul uniqu
result patient variabl stage diseas vari origin cell line order determin whether
result cell line experi applic clinic sampl ffpe mf biopsi sampl evalu
present quantifi level express although correl diseas stage
level evid express increas worsen lesion sever addit pharmacodynam
gene signatur up-regul mf biopsi sampl especi relat t-cell activ
surviv pathway signal down-regul mf ctcl cell line treat cobomarsen
convers checkpoint regul gene down-regul biopsi sampl up-regul
cobomarsen treat cell line show figur impli pathway dysregul mf revers
inhibit
figur pharmacodynam biomark comparison cobomarsen-tr cell clinic
pharmacolog inhibit use systemically-deliv complementari oligonucleotid previous
shown caus de-repress downstream target decreas tumor growth xenograft mous
model hematolog malign highlight vivo potenti cobomarsen
zhang et al lna-medi silenc low-grad cell lymphoma blood
cobomarsen addict lymphoma
mycosi fungoid mf common cutan t-cell lymphoma ctcl primari
cutan cell lymphoma ctcl form non-hodgkin lymphoma t- b- natur killer
nk cell origin ctcl compris heterogen group lymphoma differ system lymphoma
adult cell leukemia/lymphoma atll mycosi fungoid mf common form ctcl
affect person us mf origin cell resid skin may also involv lymph
node blood viscer organ confus szari syndrom ss erythroderm leukem
variant mf classifi separ form ctcl although main caus malign unclear
sever factor propos includ genet epigenet alter transloc delet
chromosom segment exposur solvent chemic high level symptom mf
includ rash-lik skin red dri skin enlarg lymph node sever itch significantli impact qualiti
life impair sleep patient also often experi skin infect due breakdown skin lesion site
cellular level mf character clonal expans cell often lack express
marker malign cell attract dermi keratinocyt dermi
malign cell travel toward cluster around langerhan cell form pautrier microabscess malign
cell also travel nearbi lymph node slip circul cutan cell
shown overexpress ctcl result induct pathway involv cellular prolifer
subsequ uncontrol clonal cell expans upregul directli correl upregul
variou interleukin name known peripher mediat pruriti debilit symptom
initi evalu patient mf includ skin biopsi immunophenotyp cell marker evalu
clonal cell receptor rearrang case suspect lymph node involv cervic auxiliari
inguin lymph node biopsi perform submit patholog review standard stage system
mf outlin figur miragen aim initi address patient stage ib- stage diseas figur
blue box patient cancer lesion cover skin surfac may includ patient
abnorm peripher lymph node absent low blood tumor involv absenc
viscer involv approxim patient present stage ia-iia diseas patient
 et al pruriti cutan t-cell lymphoma review journal american academi dermatolog
figur iscl/eortc classif mf ss
need toler durabl therapi mf mf chronic diseas patient often
move system therapi associ multitud side-effect cur treatment option
allogen hemopoiet stem cell transplant allo-hsct limit patient advanc diseas
therefor goal treatment improv symptom postpon progress use agent toler
profil outlin typic treatment option mf patient figur therapi outlin blue box
often use patient earli mid-stag mf stage ib-iii shade red risk safeti issu associ
therapi although respons durabl select treatment often accompani safeti
concern complianc issu
figur summari treatment option patient mf
mention earlier roughli stage ia-iia patient develop progress diseas patient early-stag
diseas stage ib-iia often receiv psoralen uva puva phototherapi local superfici radiotherapi
patient often relaps follow receiv bexaroten interferon alpha total skin electron beam tseb
pivot studi ctcl
orr pt
mavor studi poteligeo vs zolinza ib-ivb mf ss
orr mf poteligeo zolinza
mdor mf poteligeo zolinza mo
pivot studi ctcl
therapi although respons durabl tseb complet remiss cr relaps free
surviv patient may relaps extens cutan patch plaqu point patient may
altern interferon alpha mainten therapi puva oral bexaroten low dose tseb patient
progress later stage diseas prognosi becom bleaker merck nyse zolinza vorinostat
celgen celg istodax romidepsin approv histon deacetylas hdac inhibitor
treatment ctcl includ patient mf agent often use second line treatment fail
present respons rate safeti profil therapi figur orr rate mf patient rang
respons durat rang month frequent sae hdac inhibit
thrombocytopenia neutropenia fatigu may limit use especi among elderli patient miragen
cobomarsen demonstr favor safeti profil phase studi patient mf show sae
abnorm liver function platelet count
figur efficaci hdac inhibitor mf
orr pt
patient advanc diseas iib-ivb repres area unmet need patient cycl puva
chemotherapi hdac inhibitor interferon radiotherapi patient advanc stage mf
larg cell transform often character express marker preferenti express lymphoma
cell seattl genet adcetri brentuximab vedotin approv patient primari
cutan anaplast larg cell lymphoma pcalcl express mf receiv prior system
therapi pivot studi evalu adcetri compar physician choic therapi posit alcl
mf adcetri show orr last least month compar subject
treat physician choic therapi median progress free surviv adcetri treat subject
month compar month physician choic arm term safeti grade peripher neuropathi
observ patient adcetri treat patient discontinu treatment due
c-x-c motif chemokin receptor chemokin receptor highli express infiltr cell
patch plaqu associ mf advanc stage mf number c-c chemokin receptor
posit cell increas skin lesion mf tumor kyowa hakko kirin tyo poteligeo mogamulizumab
recent approv patient relaps refractori mf ss least one prior system therapi
pivot studi evalu drug met primari endpoint investigator-assess poteligeo compar zolinza
mpf month vs month orr across patient poteligeo treat
subject compar zolinza arm orr mf patient treat poteligeo
compar subject treat zolinza dor mf patient treat poteligeo
month versu month compar arm term safeti sae includ rash infus relat
reaction lower respiratori tract infect renal insuffici drug discontinu
patient often rash drug erupt patient advanc diseas often refectori
hdac inhibit chemotherapeut regimen consid allo-hsct patient treat poteligeo
increas risk sever steroid-refractori graft-versus-host diseas gvhd transplant relat death
may limit use although variou treatment option mf patient either experi relaps
initi treatment encount side effect restrict use result need well toler therapi
maintain effect overtim miragen current evalu cobomarsen phase studi patient
hematolog malign includ mf atll therapi shown favor safeti profil
sign clinic activ
addit indic expans potenti cobomarsen miragen pursu expand develop
cobomarsen multipl lymphoma leukemia includ diffus larg b-cell lymphoma dlbcl adult t-
cell lymphoma/leukemia atll chronic lymphocyt leukemia cll rational behind expans
one commonli up-regul mirna varieti hematolog malign includ
lymphoma activ b-cell origin high level express associ poor prognosi
make potenti valuabl therapeut target
dlbcl preval subtyp non-hodgkin lymphoma repres approxim nhl case
current treatment paradigm dlbcl vari subtyp gener includ combin rituxan
combin cyclophosphamid doxorubicin vincristin prednison r-chop mainstay therapi
relapsed/refractori dlbcl high-dos therapi follow autolog stem cell transplant patient fail
respond second-lin therapi option receiv car-t therapi novarti nyse nv kymriah
gilead yescarta approv treatment adult patient r/r larg b-cell
lymphoma two line system therapi although efficaci treatment associ sever
toxic profil common seriou advers event includ cytokin releas syndrom neurotox overal
patient refractori diseas continu poor prognosi signific toxic associ late-stag
therapi creat need toler therapi subset patient
cll slow progress b-cell hematolog malign overal surviv rate
common form leukemia adult treatment paradigm cll patient depend sever
symptom caus diseas patient limit symptomolog monitor wait watch
approach present high-risk diseas start treatment immedi cur treatment
date stem cell transplant yield durabl respons half commonli use
pult et al trend surviv chronic lymphocyt leukemia patient germani usa first decad
twenty-first centuri journal hematolog oncolog
woyach johnson target therapi cll mechan resist strategi manag
chemoimmunotherapi treatment regimen younger patient combin fludarabin cyclophosphamid
rituximab fcr howev approxim patient relaps within addit exist
subset patient refractori diseas associ extrem poor prognosi target therapi
includ nyse brutons-tyrosin kinas btk imbruvica ibrutinib recommend
treatment option patient earli relaps abbvi venclexta venetoclax inhibitor prefer
therapi follow relaps imbruvica howev major relapsed/refractori cll patient experi serial
relaps eventu move treatment center palliat symptom highlight sub-popul
larg unmet need
atll t-cell lymphocyt malign occur patient infect human t-lymphocyt viru type htlv-
diseas character four subtypes- acut lymphoma-typ chronic smolder acut
lymphoma-typ subcategori aggress associ poor prognosi name surviv rate
approxim although chronic smolder subtyp slow-grow progress acut
form patient acute/lymphoma-typ atll especi difficult treat tumor cell
present intrins resist chemotherapeut agent prefer treatment option combin
chemotherapi includ cyclophosphamid doxorubicin vincristin prednison chop hyperfracion
cyclophosphamid vincristin doxorubicin dexamethason hyper-cvad effect treatment option
current exist relapsed/refractori atll patient seek enrol clinic trial kyowa kirin
poteligeo mogamulizumab human monoclon antibodi current approv treatment
relapsed/refractori atll japan multicent phase ii studi aggress relaps atll treatment
poteligeo demonstr orr median month median os
 flower manag relaps chronic lymphocyt leukemia appli guidelin
ishida et al mogamulizumab relaps adult t-cell leukemialymphoma updat follow-up analysi phase
ii studi cancer scienc
market cobomarsen
due slow progress low mortal rate associ mf use preval estim rather
incid calcul help determin address patient popul cobomarsen estim
patient us patient europ suffer mf mf make
nhl patient popul sinc incid mf larg stabl appli growth rate equal
us eu popul addit identifi number mf patient clinic stage
diseas averag result four retrospect
phase ii solar studi evalu stage ib-iii mf patient mswat score howev earli stage
mf patient includ stage ib iia may receiv topic therapi system treatment base
conserv kol estim estim stage ib iia patient progress previou therapi
becom elig cobomarsen believ patient later stage mf includ stage iib
elig receiv cobomarsen system therapi
includ clinic studi stage ia iv mf patient like benefit cobomarsen well
given overexpress kol conserv believ patient stage ia like
progress previou therapi becom elig cobomarsen entir stage iv patient popul
suitabl therapi figur detail address patient popul cobomarsen base list
figur mf patient elig treatment cobomarsen clinic stage
clinic stage mf
 et al long-term outcom patient mycosi fungoid szari syndrom clinic prognost
factor risk diseas progress dermatol
 et al surviv outcom prognost factor mycosi fungoides/ szari syndrom valid
revis intern societi cutan lymphomas/european organis research treatment cancer stage
propos journal clinic oncolog
talpur et al long-term outcom patient mycosi fungoid szari syndrom
desai liu parker clinic characterist prognost factor surviv patient mycosi
fungoid sezari syndrom southeastern unit state single-institut cohort journal american academi
base clinic trial popul stage ib-iii cobomarsen may elig treat mf patient us
patient europ expand includ stage ia iv diseas address patient
popul would grow us europ potenti cobomarsen also expand
larger hematolog indic futur includ dlbcl cll attl base
cobomarsen shown sign clinic activ mf
miragen design clinic develop strategi intend acceler approv timelin reduc
develop risk strategi depict figur revolv around prove mechanist proof-of-concept
mpoc access indic demonstr mechanist rational compani mpoc studi provid
opportun explor develop core mechan action support genotype/phenotyp
enrich biomark strategi miragen believ mpoc find broader implic
diseas similar mechanist rational exist mpoc establish miragen envis move
clinic candid registr phase ii/iii studi miragen report mpoc data first-in-human
phase studi patient mycosi fungoid mf subtyp cutan t-cell lymphoma ctcl show
toler safeti profil sign clinic activ base find compani plan initi
registr phase ii solar studi cobomarsen patient mf miragen also explor
cobomarsen phase expans cohort across broader rang indic includ adult t-cell
lymphoma/leukemia atll diffus larg b-cell lymphoma dlbcl chronic lymphocyt leukemia cll
figur clinic cobomarsen blood cancer
interim phase safeti efficaci data cobomarsen mf atll present american societi
clinic oncolog annual meet june shown figur addit interim data
expans indic anticip
figur interim phase data cobomarsen mf atll
sae due
cobomarsen dlt
grade pruriti tumor
flare patient
event grade
patient receiv month
mdor day
decreas express activ marker
prolif index atl circul tumor cell
maintain diseas stabil cobomarsen
month
basket phase trial cobomarsen mf ctcl atll dlbcl
studi design dose-rang open-label phase studi cobomarsen patient certain lymphoma
leukemia mf cohort consist distinct part part enrol cohort mf patient receiv
intratumor inject cobomarsen mg either day follow-up addit
day mf patient enrol part studi receiv either subcutan intraven dose cobomarsen
rang mg allow remain stabl background therapi first patient treat
section elig receiv studi drug week subsequ patient allow continu
therapi indefinit depend upon respons toler compani design studi incorpor
hematolog malign overexpress name cll dlbcl atll patient
enrol portion studi elig receiv either subcutan intraven cobomarsen singl
agent patient receiv dose cobomarsen mg first week follow mg dose
cobomarsen
primari outcom across entir studi safeti toler cobomarsen base vital sign physic
examin clinic laboratori test incidence/sever advers event secondari endpoint across
indic pharmacokinet measur progress free surviv durat respons overal surviv time
progress studi also evalu patient report outcom treat subject miragen expect releas
addit data mf cohort annual american societi hematolog meet decemb
assess defin respons mf understand lesion respons rate measur key
evalu efficaci candid therapi treatment mf common method skin score
modifi sever weight assess tool swat measur involv direct assess bodi
surfac area bsa mf ss lesion across area bodi multipli sum bsa
lesion lesion patch plaqu lesion tumor phase studi
miragen weight tumor mswat assess tool depict figur current guidanc recommend
mswat assess perform bedsid investig across time point order
elimin inter-observ variabl definit respons skin lesion patient mf ss
depict figur miragen use mswat evalu measur respons cobomarsen treatment
phase studi patient mf mswat use measur overal respons rate four month
figur mswat definit respons skin mf/ss patient
preliminari result ctcl overal treatment cobomarsen safe well toler seriou
advers event attribut dose-limit toxic dlt report one patient experienc
incid pruriti associ subcutan mg dose cobomarsen second associ
intraven mg dose drug second dlt grade tumor flare report patient receiv
mg intravenous-bolu dose drug common treatment-rel neutropenia
olsen et al clinic end point respons criteria mycosi fungoid sezari syndrom consensu
statement intern societi cutan lymphoma unit state cutan lymphoma consortium
cutan lymphoma task forc european organis research treatment cancer clin
querfeld et al phase studi safeti efficaci cobomarsen synthet inhibitor microrna-
ctcl patient annual meet dec
 et al phase studi cobomarsen cobomarsen cutan t-cell lymphoma
associ t-cell leukemia/lymphoma abstract present
inject site pain fatigu treatment relat grade includ neutropenia pruriti
decreas lymphocyt count acut inflammatori toxic signific abnorm
detect liver kidney address key safeti concern associ mirna therapeut
evalu other past
term efficaci april system treatment cobomarsen lead mswat score improv
ctcl patient consist improv iv infus cohort shown figur
greater mswat reduct seen patient receiv cobomarsen
subcutan iv iv bolu formul month mswat iv cohort mention
earlier patient stage ib-iii mf often cycl therapi includ puva interferon alpha retinoid
inde januari patient experienc mswat improv studi receiv
concomit system therapi bexaroten interferon alpha methotrex vorinostat plu either
subcutan iv cobomarsen remain patient receiv subcutan iv cobomarsen
monotherapi sinc studi report addit patient experienc mswat improv april
howev know statu background therapi patient
figur mswat score improv system cobomarsen treatment
term durat respons patient treat system month reach overal
respons rate last month shown figur patient reach receiv
cobomarsen monotherapi receiv iv cobomarsen receiv subcutan formul patient
receiv subcutan cobomarsen achiev respons later relaps patient continu therapi
data cutoff april mean durat respons day patient receiv dose
cobomarsen also demonstr consider improv qualiti life measur total
score miragen expect report addit data studi upcom american societi hematolog
annual meet decemb
figur durat respons cobomarsen treat patient
preliminari result cobomarsen atll miragen recent report preliminari data patient
american societi clinic oncolog meet june patient previous diagnos
acut leukem diseas lymphomat diseas respect patient diseas well-
control zidovudin interferon lenalidomid epoch chemotherapi upon treatment
cobomarsen patient experienc stabil tumor cell count peripher blood last month
demonstr figur addit cobomarsen treatment result normal lymph node
evid follow ct scan perform may
figur decreas tumor cell treatment cobomarsen patient
patient maintain stabl lymphadenopathi cobomarsen treatment previous reduc
significantli choep chemotherapi maintain stabl peripher blood tumor cell count month
miss dose cobomarsen follow increas percent tumor cell peripher lymphocyt
popul shown figur decreas reiniti therapi togeth data provid level
proof-of-concept cobomarsen atll safeti issu note patient asid singl treatment-
relat event nausea resolv within hour
figur effect cobomarsen treatment atll patient
solar phase ii clinic trial mycosi fungoid
studi design random parallel open-label double-blind studi cobomarsen depict
figur patient stage ib-iii mf receiv least one prior therapi ctcl
mswat score approxim patient random cobomarsen vorinostat arm
follow progress death month patient cobomarsen arm expect receiv mg
iv infus primari endpoint phase ii studi overal respons rate four month use global
respons criteria progress free surviv key secondari endpoint exploratori endpoint
patient report outcom includ pain itch solar studi power detect differ
cobomarsen vorinostat arm
miragen formul multipl registr path cobomarsen inform talk fda
rout approv follow
approv acceler basi posit measuresshow superior vorinostat
manag believ posit data alon may submit acceler approv although
subject review fda
full approv separ posit readout measur readout time
miragen expect gain full approv acceler basi
note fda establish specif orr rate need attain approv also
given guidanc comparison agent fact miragen cobomarsen need show
superior vorinstat particular studi
cobomarsen competit landscap need therapi toler long-
last ctcl
shown figur asset pipelin ctcl therapi robust varieti target test treat
variou stage subset diseas know upregul contribut
prolifer mf tumor yet fulli understand de-repress lead benefici clinic
respons howev compani believ cobomarsen uniqu posit compar asset
pipelin given role global gene regul rather target singl biomark decreas level
expect multipl downstream effect inflammation/immun cancer-rel target gene
ultim provid multifacet approach treat diseas
figur select therapi develop ctcl
phase ii studi ctcl
compar placebo
recurr
case sever vascular leak
klade et al recombin toxin fusion protein patient cutan t-cell lymphoma
respons median
phase ib ctcl
interim phase
orr
cr
phase ctcl
interim phase result
malign orr mf
underappreci market opportun t-cell lymphoma mention earlier larg unmet need
remain mf ctcl whole given limit efficaci unfavor toxic profil associ
current avail system therapi kol note mf patient tend go continu cycl treatment
respons diseas progress prompt greater physician attent toward safeti qol metric
therapi prescrib bar regulatori approv develop mf therapi therefor rel low
long asset demonstr sustain level efficaci form well toler without
signific advers event like use clinic set
base low barrier entri well array biomark target mf repres much larger
opportun previous thought believ mani drug develop includ cobomarsen
expand broader stage mf well malign limit treatment option atll base
express respect biomark earli clinic develop cobomarsen possibl
becom standard care mf phase orr mean durat respons
day compar better pipelin therapi importantli drug
associ treatment-rel advers event thu far assum data transferr
registr studi cobomarsen potenti treatment landscap mf t-cell lymphoma
khodadoust et al pembrolizumab treatment relapsed/refractori mycosi fungoid szari syndrom
clinic efficaci citn multicent phase studi world congress cutan lymphoma abstract present
hultberg et al express cutan cell lymphoma ctcl patient mechan action
skin histopatholog clinic data intern confer malign lymphoma
bagot et al relapsed/ refractori ctcl result first human multicent phase studi
miragen context mirna therapeut platform failur develop rna interfer
rnai base therapi expand dramat sinc fire mello origin discoveri rnai
ambro find mirna past decad flurri therapeut small interf rna
sirna mirna made way pipelin biopharmaceut compani aim either silenc
target imping regulatori network involv diseas major rna-bas program
zero area oncolog rare genet disord silenc one target modul express
regul case cobomarsen oncomir potenti elicit meaning therapeut respons
promis therapeut class led creation variou pure-play startup follow acquisit
collabor licens deal larg pharma player howev interest field wane due complic
regard stabil rna therapi mode deliveri unwant innat immun respons fact mani
big pharma compani shutter rnai-bas program includ merck shut rnai-program
follow acquisit rnai-biotech sirna therapeut roch close intern research
program follow invest howev despit setback rnai-therapeut begin gain
traction follow year approv alnylam onpattro patisiran polyneuropathi
hereditari amyloidosi recent posit data program
approv cap drug develop path includ variou hurdl ultim progress relat
design deliveri rnai-bas therapi
concern relat safeti rnai-bas therapeut blue box figur born across multipl clinic
program variou indic includ hepat oncolog cardiac diseas mani program
discontinu shown figur failur result effort aim develop appropri chemic
modif deliveri method rnai-bas agent common chemic modif includ lock nucleic
acid lna chemistri ribos group modif well addit phosphorothio
boranophosph oligo backbon sever novel deliveri method also develop includ viral
vector polymer-bas system lipid-bas system red box figur non-vir vector prefer viral
carrier associ higher risk lethal immunogen respons
fire et al potent specif genet interfer double-strand rna caenorhabd elegan natur
rc et al elegan heterochron gene encod small rna antisens complementar
figur select current previou develop
case
liver toxic
grade
n/a human data
case sever
death sever
discontinu due
lack efficaci
histor nake drug-deliveri reserv local deliveri method lack target specif stabil
administ system recent data evalu uptak traffick nake oligonucleotid suggest
phosphorothio oligonucleotid preferenti bind plasma protein cell maintain
bodi longer period time moreov evid malign cell case leukem cell show
greater oligonucleotid uptak compar match normal cell vitro import note
miragen develop cobomarsen naked-drug iv system formul ctcl compani believ
go indic may circumv need special deliveri vehicl lipid nanoparticl
potenti avoid treatment-rel immune-sid cobomarsen product screen identifi
candid activ contain lna phosphorothio modif backbon
design aid stabil increas uptak cell date cobomarsen associ acut
immun liver toxic sae report term efficaci cobomarsen demonstr earli
sign therapeut activ view data encourag believ data respect safeti
durabl help better understand therapeut benefit end miragen plan releas addit data
on-going phase studi annual american societi hematolog meet decemb
expect initi registr phase ii solar trial next mileston expect posit
compani furthest along develop among mirna therapeut cancer figur green box
kol consult highlight unrecogn area need mf initi assess cobomarsen
kol spoke view safety/toler durat respons key factor new therapi seek
address mf accord kol consult manag later stage mf patient prevent stage
ib diseas progress stage iib beyond press unmet need indic one
kol highlight latter far impact given chronic natur mf mean patient often
cycl differ treatment combinatori regimen associ short-liv efficaci
assess therapi enhanc durat respons critic mention earlier conserv
estim suggest stage ib iia patient relaps progress diseas receiv avail
treatment exampl respons rate puva high cr orr howev durabl
rare hdac inhibitorssuch romidepsen vorinostat approv treatment ctcl
includ mf induc orr rate last month note vorinostat show orr
head head studi mogamulizumab orr mf patient median durat respons
month patient treat vorinistat compar month mogamulizumab arm seattl genet
brentuximab vedotin recent approv express mf patient receiv prior system
mpf month howev consult highlight patient elig
treatment requir posit often associ late stage diseas stage iv
kol consult also highlight need therapi long-term favor safeti profil given
prolong use current treatment option interferon alpha retinoid radiat hdac inhibitor
associ side effect kol highlight key safeti concern current system treatment depict
figur turn influenc treatment decis patient perspect kol identifi
complianc access conveni factor influenc patient qualiti life specif identifi
fatigu gi side effect associ hdac therapi issu affect patient complianc accord
zhao et al olignucleotid uptak human hematopoiet cell increas leukemia relat cellular
 et al lipid-bas nanocarri rna deliveri current pharmaceut design pp
increas use add-on therapi
mitig aforement
save later line therapi use
preclud patient receiv hsct
given indefinit due
kol chronic natur diseas mean patient want remind malign
therefor therapi access requir prolong inpati admiss desir
figur side effect identifi kol associ system therapi mf
kol survey overview mf treatment landscap highlight cobomarsen safeti profil attract
grade pruritis/tumor flare neutropenia suggest far efficaci data impli
drug activ eager see data regard efficaci durabl miragen slate initi
registr phase ii solar studi
remlarsen gener mimic microrna treat fibrot
develop remlarsen mirna mimic base compani proprietari
microrna platform cutan fibrosi fibrot indic unlik cobomarsen microrna antagonist
select inhibit cellular mirna remlarsen act microrna replac otherwis known mirna
mimic promir restor mirna level period downregul preclin data remlarsen suggest
play role downregul fibrot gene potenti decreas fibrot burden multipl
organ includ lung heart liver recent phase studi healthi volunt show remlarsen
safe toler dose mg subject receiv intraderm inject remlarsen report mild
treatment-rel advers event though mild-to-moder inject site reaction observ subject
receiv remlarsen data readout on-going phase ii trial remlarsen patient histori keloid
expect miragen recent publish preclin data suggest mechanist proof concept ocular
fibrosi also explor potenti mimic patholog associ fibrosi
mechanist rational remlarsen synthet oligonucleotid mimic one three member
famili famili compris known regul
host fibrot gene across multipl organ includ heart liver kidney typic around nucleotid
length oligom play key role regul extracellular matrix ecm also contribut
cell prolifer differenti three share ident seed region use identifi target
rna highli conserv human mice rat suppress express target gene
bind sequenc untransl region utr specif mrna facilit degrad
physic repress shown figur tgf- known mediat downregul
fibrot process result pathogen upregul extracellular matrix ecm gene subsequ
figur pathway affect express
schemat remlarsen present figur antisens strand ident
engin uu overhang number modif increas stabil altern
sens strand act stabil passeng strand thu modifi prevent interfer
antisens strand o-methyl reduc chanc load rna-induc silenc complex risc
kriegel famili genom cell biolog relev renal cardiovascular injuri physiol genom pp
lam kw et al sirna versu mirna therapeut gene silenc mol ther nucleic acid
facilit mirna-rna recognit design mismatch antisens strand
prevent activ cholesterol modif ad enhanc cellular uptak
figur schemat map remlarsen
line miragen development strategi progress de-risk remlarsen develop cutan
fibrosi prior potenti expans program challeng area lung eye heart fibrosi
although preclin data publish miragen provid mechanist rational behind develop remlarsen
area cutan fibrosi provid attract start point establish proof concept mechanist rational
behind remlarsen human sinc off-target safeti concern histor plagu rnai therapi possibl
local deliveri lack system exposur like key indic appeal miragen chosen target
keloidosi model cutan fibrosi first advanc remlarsen
keloid scar keloid scar form result aberr wound heal process disorgan collagen deposit
exampl keloid shown figur keloid occur year skin trauma infect wound
without prior injuri predispos present frequent ear lobe shoulder sternal
notch regress although mani way benign keloid cosmet unfavor
may present discomfort pruritu pain skin sensit first-lin treatment keloid includ
pressur therapi corticosteroid unrespons scar excis perform combin
adjuv techniqu pressur radiotherapi perform excis alon often result high reoccurr
rate although keloid occur anyon gener common individu darker skin color
suggest genet compon predisposit keloid estim incid rate popul
african interestingli keloid format involv patholog upregul tgf- key repressor
suggest mechanist rational remlarsen
gauglitz et al hypertroph scar keloid pathomechan current emerg treatment mol
wolfram et al hypertroph scar keloids- review pathophysiolog risk factor
remlarsen ocular fibrosi miragen explor mimic remlarsen fibrot indic
includ cutan ocular fibrosi well idiopath pulmonari fibrosi ipf evid
regul fibrot process rang tissu includ lung heart assum efficaci
cutan fibrosi ocular fibrosi present attract next target due possibl local drug deliveri
topic administr compani recent announc preclin data remlarsen detail anti-fibrot
activ rat appli topic eye corneal ulcer addit penetr cornea post-
injuri without evid local toxic remlarsen decreas scar format increas corneal epitheli thick
reduc number actin posit myofibroblast stroma comparison placebo remlarsen inhibit
express pro-fibrot gene day injuri signifi engag keratocyt
myofibroblast
previou preclin studi remlarsen shown readili taken cornea topic administr
retin layer intravitr inject vitro remlarsen inhibit express collagen primari
ips-deriv human retin pigment epitheli cell inhibit express downstream target gene
vivo rabbit model prolif
although ocular fibrosi lead haze eventu vision loss current avail pharmacolog
therapi avail prevent treat diseas base preclin data miragen expect initi human
clinic trial remlarsen ocular fibrosi follow corneal trauma infect ulcer degen diseas
potenti next-gener mimic fibrot indic miragen explor next-gener
mimic fibrot indic ipf preclin data bleomycin-induc murin model
pulmonari fibrosi show inject mimic prevent collagen deposit maintain fibrosi level
rooij et al dysregul microrna myocardi infract reveal role cardiac fibrosi
knabel et al system deliveri amelior hepat fibrosi carbon tetrachloride-tr
octob announc present data preclin studi
demonstr potenti anti-fibrot effect remlarsen cornea oligo meet seattl wa
gallant-behm propp ss jackson al inhibit ocular fibrosi mimic
par seen disease-fre control error bookmark defin demonstr clearli histolog stain
 lung tissu shown figur fibrot tissu evid salin control-tr bleomycin group
histolog bleomycin mice treat appear par disease-fre anim mimic
also attenu exist collagen normal express collagen gene model
pre-exist fibrosi regul aforement gene also shown dose-depend ex vivo human ipf
cell suggest anti-fibrot potenti mimic may relev human
figur histolog stain lung tissu fibrot disease-fre mice
miragen current explor potenti aerosol deliveri ipf work done
collabor lovelac respiratori research institut lab yale school medicin fund
nih aerosol provid potenti pathway local deliveri lung avoid
system exposur rat model system drug exposur inhal appear low base data follow
singl administr mg/kg mimic level heart liver spleen tissu
quantif level kidney plasma level detect hour administr
mg/kg dose nebul like mechanist similar iv formul assess prior
studi figur suggest bleomycin-induc rat model ipf once-daili exposur aerosol mrg-
result dose-depend decreas target gene day par ipf medic pirfenidon
montgomeri feasibl distribut efficaci inhal oligonucleotid mimic pulmonari fibrosi induc
bleomycin rat
figur aerosol vs pirfenidon bleomycin-induc ipf
fibrosi market whole repres attract target miragen due high unmet need space
mechanist proof concept establish cutan fibrosi remlarsen potenti expand
varieti indic base implic fibrot process across tissu exampl ocular
fibrosi associ visual impair blind repres larg area unmet medic need
antimetabolit mitomycin standard care prevent ocular fibrosi
link tissu damag infect scare ocular fibrosi consequ post-op scare
undergo glaucoma filtrat surgeri repres larg market glaucoma second lead caus blind
us account case diseas curabl surgeri often use curb
vision loss estim million american glaucoma result clear need anti-fibrot
treatment prevent scare eye surgeri figur outlin anti-fibrot gene target use
figur anti-fibrot gene target
hemagglutin viru japan
yu-wai-man et al lifesci capit
addit ocular fibrosi indic remlarsen may mechanist valid includ ipf cardiac fibrosi
follow acut myocardi infract mi liver fibrosi nafld/nash ipf alon
lack clearli efficaci therapi point strong unmet need space combin regimen prednison
azathioprin n-acetylcystein use standard care ipf result nih trial confirm
harm effect regimen includ increas hospit risk result treatment
void partial fill fda approv roch antifibrot agent esbriet pirfenidon
boehring ingelheim privat kinas inhibitor ofev nintedanib ipf market potenti thu underscor
sale esbriet ofev total million million us million
billion world-wide nafld/nash anoth highli sought-aft fibrosi space character lack
efficaci treatment substanti unmet need nafld effect estim million adult us
preval nash expect rise
safeti toler remlarsen assess four-part placebo-control double-blind phase
studi healthi volunt primari endpoint studi safeti toler secondari outcom
includ pharmacokinet measur level skin follow treatment part establish baselin
pharmacodynam endogen level express variou gene healthi volunt subject
receiv sutur skin incis lower back biopsi obtain prior incis well
day seen figur level decreas significantli incis decreas
raghu et al prednison azathioprin n-acetylcystein pulmonari fibrosi engl pp
gallant-behm rna base modal effect treatment multipl fibrot condit anti-fibrot
accompani upregul target gene includ protein involv ecm regul
eln member collagen famili etc
figur level fibrot gene express follow incis volunt
figur show overview trial design part b-d assess safeti toler variou dose
remlarsen part singl ascend dose phase assess mg remlarsen intact skin part
particip receiv two incis one right left side lower back one excis treat
intraderm inject remlarsen salin control part assess singl ascend dose
mg mg mg incis skin altern part multipl ascend dose arm assess dose
part administ monday wednesday friday two week incis skin
figur phase trial design remlarsen part b-d
gallant-behm et al translat pd biomark preclin model mechanist proof concept
remlarsen well toler dose total mild-to-moder inject site reaction observ
subject receiv reaction appear correl dose level frequenc
treatment-rel advers event infrequ mild sever includ headach chill fatigu
weak microscop hematuria pain inject site local inject result low level system exposur
plasma accumul follow multipl dose tmax rang minut hour furthermor repeat
dose increas remlarsen presenc tissu substanti rel singl dose remlarsen biomark
valid human track chang fibrot gene express follow singl dose drug clearli
shown figur target gene upregul incis wound rel unwound skin singl
inject remlarsen three assess dose result overal downregul target gene
figur chang gene express follow singl dose remlarsen
initi evid remlarsen abil prevent fibrosi also demonstr incis skin wound base
histolog assess subject remlarsen treatment significantli decreas area fibroplasia rel
salin control meanwhil trend target gene repress follow multipl remlarsen dose
observ microrna analysi patient dose cohort part importantli chang
gene express follow remlarsen administr significantli correl chang fibroplasia area
seen figur data suggest attenu gene regul remlarsen may direct impact
gallant-behm et al pharmacodynam activ mimic human skin incis societi
figur correl remlarsen-medi chang gene express fibroplasia
phase ii studi remlarsen patient histori keloid miragen begun recruit patient
phase ii studi assess safeti toler efficaci remlarsen prevent keloid scar format
random double-blind placebo-control trial approxim subject histori keloid subject
consid histori keloid previous experienc greater keloid
histor develop keloid larger cm particip undergo sutur incis biopsi left
right side upper back one wound treat intraderm mg remlarsen time
week receiv placebo control addit treatment cycl may initi sign
keloid format either wound becom appar long-term safeti effect keloid format
assess follow-up period primari endpoint studi proport keloid format
treat vs untreat wound proport subject develop keloid number particip
trae success primari endpoint determin year-long follow-up period secondari
pharmacokinet measur includ area plasma concentr vs time curv auc peak plasma
concentr day time keloid format volum form keloid also assess data
trial expect
mirna therapeut develop miragen
inhibitor promot angiogenesi
miragen pursu develop inhibitor use ischem heart failur
incision complic preclin studi shown abl increas angiogenesi
collater vessel growth preclin mous model chronic myocardi ischemia asset develop
collabor privat intern pharmaceut compani key player
develop therapi cardiovascular diseas servier respons lead global clinic develop
well potenti commerci countri besid us japan miragen retain
commerci right product us japan addit serv extens
on-going collabor miragen servier establish agreement miragen
receiv up-front two previous lead cardiovascular program
compani also elig regulatori commerci mileston well double-digit royalti
retain commerci right product us japan develop
separ phase studi evalu safeti toler either local system administ
updat studi expect
clinic data discuss current assess two on-going phase clinic trial first phase
trial random double-blind placebo-control singl multipl ascend dose trial investig
safeti toler pharmacokinet pharmacodynam follow skin excision wound creation
healthi studi enrol approxim volunt receiv singl ascend dose multipl
ascend dose intraderm inject particip experiment arm receiv
inject two wound site intraderm placebo inject two wound site particip
control arm receiv intraderm placebo inject wound site primari endpoint studi
number subject treatment-rel advers event key secondari measur includ auc cmax
second phase trial assess safeti toler pharmacokinet follow singl escal
intraven dose young healthi male studi anticip enrol subject
receiv either increas dose increas dose placebo primari endpoint incid
treatment-rel advers event key secondari measur includ auc plasma half-lif cmax studi
initi data expect
inhibitor treat neurodegener
chronic inflamm central nervou system shown key driver neurogen diseas
miragen current aim develop therapeut approach modul pathway involv inflamm
believ could key player inflammation-medi suppress neurogenesi alter
level significantli upregul famili sporad form amyotroph
later sclerosi al character progress neurodegener motor neuron brain
spinal cord classifi famili sporad al latter account
case pre-clin studi demonstr administr oligonucleotid superoxid
dismutas mice als-model achiev broad distribut result signific surviv extens
longer diseas durat treat mice miragen explor possibl target use mrg-
inhibitor neurogen patholog al
 et al method widespread inhibit prolong surviv als-model mice
miragen intellectu properti portfolio consist issu patent pend applic composit
matter method use patent applic cobomarsen current pend us pct
expect issu next two three year expir
composit matter method use patent issu octob expir june
addit issu patent pend applic possibl expir date rang
cover therapeut use gener composit matter
composit matter patent remlarsen issu june expir septemb miragen
also issu patent pend applic cover therapeut use gener composit
remlarsen possibl patent expir rang
presid chief execut offic co-found
marshal ph miragen presid chief execut offic co-found director prior
establish miragen dr marshal vice presid technolog busi develop bioscienc
thermo fisher scientif role respons lead technolog assess strateg plan
thermo fisher bioscienc divis unit revenu approxim billion manufactur
suppli wide rang product servic across general-chemistri life-sci arena
dr marshal one scientif founder dharmacon inc acquir fisher scientif
serv execut vice presid research oper gener manag prior
join dharmacon dr marshal serv mani capac inc recent associ director
research head research head nucleic acid peptid technolog depart
posit particip wide varieti therapeut develop approach throughout drug discoveri
process lead develop clinic candid
dr marshal earn biochemistri univers wisconsin-madison ph chemistri
laboratori professor marvin univers colorado boulder author co-author
research paper patent dr marshal current serv board fluorofind llc
jason leveron miragen chief offic capac overse compani financi
account oper function prior join miragen mr leveron senior director financ
control replidyn inc publicly-trad biotechnolog compani replidyn play import role
complet compani initi public offer execut strateg sale inc prior
join replidyn mr leveron corpor control creekpath system inc intern softwar
develop compani commenc profession career account firm ernst young llp
serv audit manag arthur andersen llp
mr leveron certifi public account hold bachelor scienc busi administr
bryant univers smithfield rhode island
adam levi miragen chief busi offic mr levi bring year advisori experi primarili
life scienc sector miragen prior join miragen senior vice presid wedbush secur
serv sinc healthcar invest bank group mr levi expertis corpor strategi
 partner experi complet billion financ advisori transact prior
join wedbush held posit increas respons invest bank merril lynch jefferi
mr levi earn appli econom cornel univers
execut vice presid research develop
dr rubin year industri experi prior join miragen dr rubin senior vice presid
research develop chief medic offic xoma ltd chief execut
offic resolvyx pharmaceut inc presid chief execut offic critic
therapeut inc
dr rubin associ sepracor serv senior vice presid develop
later execut vice presid research develop respons lead success
develop mani sepracor intern develop approv product includ xopenex lunesta
xopenex hfa brovana
paul held senior level posit glaxo-wellcom recent vice
presid world-wide clinic pharmacolog earli clinic develop associ abbott
includ vice presid immunolog endocrinolog success advanc zileuton
first approv inhibitor discoveri approv treatment asthma
dr rubin receiv ba occident colleg rush medic colleg board certifi
intern medicin complet post-gradu train univers wisconsin hospit clinic
risk invest
consid invest miragen high-risk invest miragen develop stage compani
histori take treatment market current fda approv drug portfolio earli indic
efficaci necessarili translat posit late-stag result compani reata may unabl
obtain suffici capit fund plan develop program regulatori risk associ
develop drug reata may receiv fda approv candid despit signific time
financi invest regulatori approv market sell drug guarante drug penetr
market sale may meet expect
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
